Moreover, a multicenter Italian investigation (29) indicated that HER2-low status has independent negative prognostic value in patients with HoR-positive/HER-negative advanced BC treated with CDK4/6i with ET as first-line therapy. This evidence concerns the gene ERBB2 and breast cancer.